Serum CXCL13 was significantly higher in prostate cancer patients compared to patients with benign prostatic hyperplasia or high-grade prostatic intraepithelial neoplasia and normal healthy donors, suggesting that CXCL13 is a better predictor of prostate cancer than PSA [58]. This evidence concerns the gene KLK3 and prostate intraepithelial neoplasia.